On the stock market since 2022, it operates in the world of health and science. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 4,719% a year over the last 4 years. Red columns mark years that ended in a loss.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 26% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 2,276% a year on average.
The company sells $54.3B a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 9 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $0 against $54.3B in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, SSIC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SSIC has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.